IMM2520

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. · Phase 1 active Small molecule

At a glance

Generic name	IMM2520
Also known as	IMM2520 is a recombinant bispecific monoclonal antibody with high affinity to the dual targets, PD-L1 and CD47
Sponsor	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IMM2520 CI brief — competitive landscape report
IMM2520 updates RSS · CI watch RSS
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. portfolio CI